Depression has been hypothesized to increase breast cancer risk by influencing processes involved in cancer pathogenesis such as DNA repair, alterations in the immune system, and apoptosis.[2, 3] Furthermore, animal studies have suggested that antidepressant treatment, specifically selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), could increase breast cancer risk through their influence on elevated circulating prolactin levels. This evidence concerns the gene PRL and breast carcinoma.